Skip to content

Research

Current Studies

Recruitment is Open

Testosterone Replacement Therapy for Assessment of Long-Term Vascular Events and Efficacy Response in Hypogonadal Men (TRAVERSE) Study
Dr. Ebenezer Nyenwe, MD - Principal Investigator
Primary Inclusion (Eligibility) Criteria:

  1. Men between the ages of 45-80 years
  2. Low testosterone levels
  3. History of heart attack, artery disease, or stroke
  4. Not currently on any testosterone replacement

Contact: Mary Beth Houston (Study Coordinator), (901) 448 2676; mepps1@uthsc.edu

Trial to Assess Chelation Therapy 2 (TACT2)
Dr. Helmut Steinberg, MD - Principal Investigator
Primary Inclusion (Eligibility) Criteria:

  1. Men and Women age 50+
  2. History of heart attack > 6 weeks prior
  3. Diabetes (type 1 OR 2) with HbA1C of 6.5% or higher at diagnosis

Primary Exclusion (Ineligibility) Criteria:

  1. Previous IV chelation in last 5 years or oral chelation in last 2 years
  2. Cigarette smoker in last 2 months

For more information, visit official study website: https://tact2.org/
Contact: Amy Bell (Study Coordinator), (901) 448-1024; asbell@uthsc.edu

Acute Macronutrient Effects on Potential Modulators of Vascular Function
Dr. Helmut Steinberg, MD - Principal Investigator
This is a pilot study with the purpose to assess how differences in food composition in meals affect changes in hormones, fat, sugar, and other substances in your blood.
Contact: Amy Bell (Study Coordinator), (901) 448-1024; asbell@uthsc.edu

Recruitment is Closed

Diabetes Prevention Program Outcomes Study (DPPOS)
Samuel Dagogo-Jack, MD (PI); Faye Hampton, RN - Study Coordinator
Sponsor: NIH/NIDDK
Participants of all races who had Impaired Glucose Tolerance between the ages of 25 with no upper age limit with a BMI of >24
Location: 920 Madison Ave. Suite 300A, Memphis, TN 38163
Contact: Phone: (901) 448-5290; ehampto5@uthsc.edu

Pathobiology and Reversibility of Prediabetes in a Biracial Cohort (PROP-ABC)
Samuel Dagogo-Jack, MD (PI); Ibiye Owei, MBBS- Study Coordinator
Sponsor: NIH
Participants are healthy individuals with either one or both parents with type 2 diabetes, age group 18-65
Contact: Fataoumatta Ceesay (901) 448-5299; fceesay@uthsc.edu

Epidemiology of Diabetes Interventions and Complications Study (EDIC)
Sam Dagogo-Jack, MD, FRCP (PI); Christine S. Wigley R.N. - Study Coordinator
Sponsor: NIH
Division of Endocrinology, Diabetes, and Metabolism
Participants are type 1 diabetics from the Diabetes Control and Complications Trial (DCCT)
Location: 920 Madison Ave. Suite 300A, Memphis, TN 38163
Contact: (901) 448-7942 E-mail: cwigley@uthsc.edu

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatide on Cardiovascular Outcomes in Type 2 Diabetes Patients at High Cardiovascular Risk (Amplitude-O)
Dr. Ebenezer Nyenwe, MD - Principal Investigator
Participants have Type 2 Diabetes Mellitus (T2DM) with high cardiovascular risk.

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients with Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal Function (SCORED)
Dr. Ebenezer Nyenwe, MD - Principal Investigator
Participants have type 2 diabetes, cardiovascular risk factors, and moderately impaired renal function.

 

Completed Studies

CAROLINA Trial

Sam Dagogo-Jack, MD (PI); Helmut Steinberg, MD - Study Coordinator
Sponsor: Boehringer Ingelheim
Type of patients for recruitment: Type 2 diabetes, H/O cardiovascular disease (previous vascular disease or evidence of vascular related end-organ damage), age = 40 and =85 years, high risk of cardiovascular events, with HbA1c 6.5-8.5% (treatment naïve) or 6.5-7.5% (treated)
Contact: Amy Bell, (901) 448-1008; asbell@uthsc.edu

A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Dapagliflozin 10 mg Once Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischemic Stroke in Patients with Type 2 Diabetes (DECLARE)
Samuel Dagogo-Jack, MD (PI); James Ekwensi, MD - Study Coordinator
Participants are Type 2 Diabetes with Cardiovascular Disease
Contact: (901) 448-2676, jekwensi@uthsc.edu

 

The Effect of Dulaglutide on Major Cardiovascular Events in Patients with Type 2 Diabetes: Researching Cardiovascular Events with a Weekly Incretin in Diabetes (REWIND)
Helmut Steinberg, MD (PI); Amy Bell - Study Coordinator
Participants are Type 2 Diabetes with Cardiovascular Disease
Contact: Amy Bell, (901) 448-1008; asbell@uthsc.edu 

Pre-Diabetes Study

Last Published: Jan 13, 2020